Experts reviewed withdrawals across fast-track drug approval programs, finding that overall, these programs contribute positively to drug development with little safety concerns.
There was little known at the time about COVID-19, particularly across patients with different underlying conditions like cancer. What was undeniable was its spread and devastating health effects.